Menicon Co Ltd (Menicon) designs, manufactures, imports, exports and sells contact lenses, medical goods, medical instruments, and medical supplies. Menicon operates manufacturing centers and sales offices across various regions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Menicon develops contact lens materials, lens care products and intraocular lenses. The company’s research and development aims at developing lenses of next- generation and conducting research from molecular design for synthesis and polymerization of raw materials. It also develops care products that match the characteristics of contact lenses. The company is focusing on developing elemental technologies, integrating market needs, and improving production efficiency while lowering manufacturing costs. Menicon is actively pursuing joint research with external partners and has been utilizing generative AI to enhance productivity in areas such as Selective Dissemination of Information (SDI) searches and patent monitoring operations. The company is working on establishing and developing myopia control technology for younger demographics, expanding product lineups, and innovating next-generation products through collaboration with research institutions. As of March 31, 2025, the company held 662 patents. The company plans to file approximately 35 patent applications annually by FY2028. In FY2025, the company spent JPY5,875 million on its R&D activities, which as a percentage of revenue stood at 4.8% and grew 14.6% YoY.